Free Trial

Lifecore Biomedical Q2 2023 Earnings Report

Lifecore Biomedical logo
$7.47 -0.16 (-2.10%)
(As of 12/3/2024 ET)

Lifecore Biomedical Earnings Headlines

Craig-Hallum Reaffirms Their Buy Rating on Lifecore Biomedical (LFCR)
I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Lifecore Biomedical Strengthens Financial Position with Key Moves
See More Lifecore Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lifecore Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lifecore Biomedical and other key companies, straight to your email.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

View Lifecore Biomedical Profile

More Earnings Resources from MarketBeat